Prophylaxis for severe haemophilia: Clinical and economical issues

Haemophilia

Volumn 9, Issue 4, 2003, Pages 376-381

  Fischer, K ^a,b   Van Den Berg, M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anthropathy; Cost; Outcome; Prophylaxis; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE;

ADULT; ARTICLE; BLEEDING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG MEGADOSE; ECONOMIC ASPECT; FRANCE; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA; HUMAN; INFUSION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; SAFETY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SWEDEN; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0037810806     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00764.x     Document Type: Article

References (31)

1. Pool JG, Shannon AE. Production of high-potency concentrates of antihaemophilic globulin in a closed-bag system. N Engl J Med 1965; 273: 1443-7.
2. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull WHO 1995; 73: 691-701.
5. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for haemophilia A: a cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
6. Bohn RL, Avorn J, Glynn RJ et al. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
7. Lusher JM. Prophylaxis in children with haemophilia: is it the optimal treatment? Thromb Haemost 1997; 78: 726-9.
8. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The orthopaedic outcome study group. J Int Med 1994; 236: 391-9.
9. Szucs TD, Öffner A, Kroner B et al. Resource utilization in haemophiliacs treated in Europe: results from the European study on socioeconomic aspects of haemophilia care. Haemophilia 1998; 4: 498-501.
10. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
11. Aznar JA, Magallon M, Querol F, Gorina E, Tusell JM. The orthopaedic status of severe haemophiliacs in Spain. Haemophilia 2000; 6: 170-6 (Abstract).
12. Van Creveld S. Prophylaxis of joint haemorrhages in haemophilia. Acta Haemat 1971; 45: 120-7.
13. Van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 107: 561-5.
14. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 7: 446-52.
15. Fischer K, Berg van den HM, Mauser-Bunschoten EP, Roosendaal G. Changing treatment strategies for severe haemophilia A: effects on joint status. A pilot study. Haemophilia 1998; 4: 177 (Abstract).
16. Fischer K, Van der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
17. Löfqvist T, Nilsson IM, Berntorp, E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
18. Fischer K, Van der Bom JG, Negrier C, Grobbee DE, Van den Berg HM. Prophylaxis versus on demand treatment for severe haemophilia: better outcome at equal costs. Blood 2001; 98 (Suppl): 533a (Abstract).
19. Fischer K, Astermark J, Van der Bom JG, Ljung RCR, Berntorp E, Grobbee DE, Van den Berg HM. Comparison of two prophylactic regimens for severe haemophilia: intermediate dose versus high dose. Blood 2001; 98 (Suppl.): 532a (Abstract).
20. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30: 3-6.
21. Pettersson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
22. Hamel J, Pohlmann H, Schramm W. Radiological evaluation of chronic haemophilic arthropathy by the Pettersson score: problems in correlation in adult patients. Skel Radiol 1988; 17: 32-6.
23. Erlemann R, Rosenthal H, Walthers EM, Almeida P, Calleja R. Reproducibility of the Pettersson scoring system - an interobserver study. Acta Radiol 1989; 30: 147-51.
24. Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia 1996; 2: 211-17.
25. Nuss R, Kilcoyne RF, Geraghty S et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000; 6: 162-9.
26. Manco Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia 2000; 6: 649-57.
27. Von Mackensen S, Bullinger M, Ravens-Sieberer U, Negrini C. Health-related quality of life in children and adolescents with haemophilia. Development of the new Haemo-Qol questionnaire. Haemophilia 2000; 6: 427 (Abstract).
28. Carlsson M, Berntorp E, Bjorkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of haemophilia A. Eur J Haematol 1993; 51: 247-52.
29. Carlsson M, Berntorp, E, Bjorkman S, Lethagen S, Ljung RCR. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
30. Astermark J, Petrini P, Tengborn L et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
31. Fischer K, Van der Bom JG, Mauser-Bunschoten EP et al. Effects of postponing prophylactic treatment on long-term outcome in patients with severe haemophilia. Blood 2002; 99: 2337-41.